Skip to content
OpenCapital
Get started

Lipocine LPCN Q4 2025 Annual earnings

Reported March 9, 2026 · Before market open

Revenue$1.1MBeat by $1.0M
EPS-$0.34Beat by $0.26
Revenue estimate$116.0K
EPS estimate-$0.60

Next report

Aug 4, 2026 (In 5 days)
Revenue estimate$213.0K
EPS estimate-$0.40

Versus estimates

Revenue

Q1 2026$1.2MBeat by $1.0M
Q4 2025$1.1MBeat by $1.0M
Q3 2025$114.6KMiss by $123.4KQ2 2025$622.8KBeat by $384.8KQ1 2025$93.9KMiss by $258.1KQ4 2024$3.5MBeat by $877.4K

Diluted EPS

Q1 2026-$0.54Miss by $0.03
Q4 2025-$0.34Beat by $0.26
Q3 2025-$0.59Miss by $0.03Q2 2025-$0.41In lineQ1 2025-$0.35In lineQ4 2024$0.33Beat by $0.73

Ask the moment Lipocine reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did Lipocine report Q4 2025 earnings?
Lipocine (LPCN) reported Q4 2025 earnings on March 9, 2026 before market open.
What were Lipocine's Q4 2025 revenue and EPS?
Lipocine reported revenue of $1.1M and eps of $-0.34 for Q4 2025.
Did Lipocine beat estimates in Q4 2025?
Revenue beat the consensus estimate of $116.0K by $1.0M. EPS beat the consensus estimate of $-0.60 by $0.26.
How did Lipocine's Q4 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue declined 67.8% from $3.5M a year earlier.
Where can I find Lipocine's Q4 2025 SEC filings?
You can read the 8-K earnings release (0001493152-26-009428) and the 10-K periodic report (0001493152-26-009411) directly on SEC EDGAR. The filing index links above go to sec.gov.